PHARMACY

Bayer, UC Berkeley work together to build biotechnology center

BY Alaric DeArment

NEW YORK Bayer and the University of California Berkeley are building a center to develop methodologies, measures and tools to improve development and production of biotech drugs, according to the East Bay Business Times.

The center, called the UC-Berkeley Center for Biopharmaceutical Operations, is scheduled to open in the middle of next year.

The ultimate goals of the center are to lower the prices of biotech drugs, which can cost patients tens of thousands of dollars, and improve manufacturing practices.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Shopko donates school supplies to Green Bay area elementary school

BY Alaric DeArment

GREEN BAY, Wis. An elementary school in Green Bay received a variety of school supplies from a locally headquartered retail chain.

Shopko announced Oct. 2 that it had donated the supplies to Sunrise River Elementary, which serves students in second through fifth grade. The supplies included basic items from the school’s required supply list.

Shopko operates stores throughout the Midwest and West.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ARCA Biopharma makes unprecedented payment to Aeolus following FDA approval of bucindolol

BY Alaric DeArment

NEW YORK Aeolus Pharmaceuticals announced Friday that it had received a $175,000 milestone payment from ARCA Biopharma following the Food and Drug Administration’s acceptance of an approval application for a cardiovascular drug.

Aeolus said the drug, bucindolol, could be the first genetically targeted cardiovascular therapy. CPEC, a company owned jointly by Aeolus and Indevus Pharmaceuticals, licensed all rights to bucindolol to ARCA.

“ARCA’s success in demonstrating the potential benefits of bucindolol in treating heart failure in patients is encouraging,” Aeolus president and chief executive officer John McManus said in a statement. “We look forward to an expeditious review and hope for a positive outcome.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?